Dr Alastair Moss is a British Heart Foundation Academic Clinical Lecturer at the NIHR Cardiovascular Biomedical Research Centre University of Leicester. Dr Moss graduated from Christ’s College Cambridge and King’s College London School of Medicine before commencing clinical training in cardiology in the Wessex Deanery. He has undertaken subspecialty training in advanced cardiovascular imaging at tertiary centres in Edinburgh Southampton and Oxford. Prior to joining the cardiovascular imaging research group in Leicester he obtained a PhD at the University of Edinburgh under the supervision of Professor David Newby and Professor Marc Dweck. He has received research funding from the Wellcome Trust Chief Scientific Office of Scotland and the British Heart Foundation. He holds positions on national (British Society of Cardiovascular Imaging) and international (Fellows and Resident Leaders of the Society of Cardiovascular Computed Tomography) cardiac imaging committees and he is an international advisory board member of the journal Heart.
Dr Alastair Moss has major research interests in using molecular imaging to better understand the pathophysiology of coronary artery disease. Dr Moss has expertise in using cardiac computed tomography to detect vulnerable atherosclerotic plaques [SCOT-HEART trial NCT01149590] and is an investigator of the Wellcome Trust funded PRE18FFIR study [NCT02607748] the first multicentre study to establish whether coronary 18F-fluoride positron emission tomography can identify patients at risk of recurrent myocardial infarction. He has investigated the clinical application of coronary positron emission tomography in the DIAMOND trial [NCT02110303] a Phase 3 randomised placebo-controlled trial using 18F-fluoride activity to guide the intensification of antiplatelet therapy.
(0) 18F-Sodium fluoride coronary uptake predicts outcome in patients with coronary artery disease
Kwiecinski J, Tzolos E, Adamson PD, Cadet S, Moss AJ, Joshi N, Williams MC, van Beek EJ, Dey D, Berman DS, Newby DE, Slomka PJ, Dweck MR. J Am Coll Cardiol. 2020;75:3061-3074.
Ticagrelor to reduce myocardial injury in patients with high-risk coronary artery plaque
Moss AJ, Dweck MR, Doris MK, Andrews JPM, Bing R, Forsythe RO, Cartlidge T, Pawade TA, Daghem M, Raftis JB, Williams MC, van Beek EJR, Forsyth L, Lewis S, Lee R, Shah ASV, Mills NL, Newby DE, Adamson PD. JACC Cardiovasc Imaging. 2020;13:1549-60.
Molecular imaging of coronary atherosclerosis using 18F-flouride
Moss AJ, Doris MK, Andrews JPM, van Beek EJR, Forsyth L, Sellers S, Leipsic J, Dweck MR, Parker RA, Newby DE, Adamson PD. Circ Cardiovasc Imaging. 2019;12:e008574.
Ex vivo 18F-fluoride uptake and hydroxyapatite deposition in human coronary atherosclerosis
Moss AJ, Sim AM, Adamson PD, Seidman M, Andrews JPM, Doris MK, Shah ASV, Bouhaidar R, Alcaide-Corral CJ, Williams MC, Leipsic JA, Dweck MR, Newby DE, Tavares AAS, Sellers SL. Scientific Reports. 2020;10:20172.
Low-density non-calcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial (Scottish Computed Tomography of the HEART)
Williams MC, Kwiecinski J, Doris M, McElhinney P, Dâ€™Souza M, Cadet S, Adamson PD, Moss AJ, Alam S, Hunter A, Shah ASV, Pawade T, Wang C, Weir-McCall J, Bonnici-Mallia M, Murrills C, Roditi G, van Beek E, Shaw LJ, Nicol ED, Berman D, Slomka PJ, Newby DE, Dweck MR, Dey D. Circulation. 2020;141:1452-1462.
Coronary artery plaque characteristics associated with adverse outcomes in SCOT-HEART
Williams MC, Moss AJ, Dweck M, Adamson PD, Alam S, Hunter A, Shah ASV, Pawade T, Weir-McCall JR, Roditi G, van Beek EJR, Newby DE, Nicol E. J Am Coll Cardiol. 2019;73:291-301.
Guiding therapy by coronary CT angiography improves outcomes in patients with stable chest pain
Adamson PD, Williams MC, Dweck MR, Mills NL, Boon NA, Daghem M, Bing R, Moss AJ, Mangion K, Flather M, Forbes J, Hunter A, Norrie J, Shah ASV, Timmis AD, van Beek EJR, Newby DE, Roditi G, McAllister DA, Berry C, on behalf of the SCOT-HEART investigators. J Am Coll Cardiol. 2019;74:2058-2070.
High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, Sandeman D, Stables C, Adamson PD, Andrews JPM, Anwar M, Hung J, Moss AJ, Oâ€™Brien R, Berry C, Finlay I, Walker S, Cruickshank, Reid A, Gray A, Collinson PO, Apple F, McAllister DA, Maguire D, Fox KAA, Newby DE, Tuck C, Harkess R, Parker R, Keerie C, Weir CJ, Mills ML, on behalf of the High-STEACS Investigators. Lancet. 2018;392:919-928.
Dr Moss contributes to undergraduate and postgraduate teaching programmes.
Get in touch for media enquiries expert opinion or interviews.